IMV 

C$1.12
24
-C$0.02-1.75% Friday 21:59

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Dividends

0%Dividend Yield
Dec 25
C$0.28
Dec 24
C$0.19
Dec 23
C$0.11
Dec 22
C$0.09
Dec 21
C$0.11
10Y Growth
15.67%
5Y Growth
24.57%
3Y Growth
35.72%
1Y Growth
N/A

Earnings

8MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
11.96
23.7
35.44
47.18
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
0Revenue
-49.9MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow IMV.TO. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Moderna
MRNA
Mkt Cap10.61B
Moderna, Inc. is a competitor because it also focuses on mRNA technology for developing vaccines and therapeutics, similar to IMV's delivery platform for immunotherapies.
BioNTech
BNTX
Mkt Cap24.99B
BioNTech SE operates in the same space as IMV, developing and commercializing immunotherapies for cancer and other serious diseases, including mRNA-based vaccines.
Novavax
NVAX
Mkt Cap1.36B
Novavax, Inc. competes with IMV in the development of vaccines for infectious diseases, using its nanoparticle vaccine technology.
Pfizer
PFE
Mkt Cap140.15B
Pfizer Inc. is a broad-based competitor, involved in the development of vaccines and therapeutics, including its partnership with BioNTech on a COVID-19 vaccine, competing with IMV's infectious disease focus.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson is involved in the research and development of vaccines and therapeutics for infectious diseases, making it a competitor in the same market as IMV.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences, Inc. competes with IMV in the development of therapeutics for infectious diseases and cancer, with a focus on antiviral drugs.
AMGEN
AMGN
Mkt Cap160.66B
Amgen Inc. competes in the biotechnology space, focusing on innovative therapeutics, including immunotherapies, which puts it in competition with IMV.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals, Inc. is known for its development of monoclonal antibodies for the treatment of cancer and infectious diseases, competing with IMV's focus areas.
Novartis
NVS
Mkt Cap237.61B
Novartis AG competes with IMV in the development of novel healthcare solutions, including vaccines and cancer therapies, through its extensive research and development efforts.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca PLC competes in the development of vaccines and therapeutics for infectious diseases and cancer, overlapping with IMV's research and development focus.

About

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX, an immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.
Show more...
CEO
Mr. Andrew Hall M.Sc.
Employees
97
Country
CA
ISIN
CA44974L3011

Listings

0 Comments

Share your thoughts

FAQ

What is IMV stock price today?
The current price of IMV.TO is C$1.12 CAD — it has decreased by -1.75% in the past 24 hours. Watch IMV stock price performance more closely on the chart.
What is IMV stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange IMV stocks are traded under the ticker IMV.TO.
What is IMV revenue for the last year?
IMV revenue for the last year amounts to 0 CAD.
What is IMV net income for the last year?
IMV.TO net income for the last year is -49.9M CAD.
How many employees does IMV have?
As of April 01, 2026, the company has 97 employees.
In which sector is IMV located?
IMV operates in the Healthcare sector.
When did IMV complete a stock split?
IMV has not had any recent stock splits.
Where is IMV headquartered?
IMV is headquartered in Dartmouth, CA.